OFX Group (OFX)

We remain particularly attracted to OFX’s increasing global scale, strong margins and cashflow, and early evidence of multi-year investments beginning to bear fruit. Overweight.

Immutep (IMM)

Despite weathering tough macro market conditions, we view Immutep as a standout in the biopharmaceutical space.